Newswire (Published: Monday, April 1, 2019, Received: Monday, April 1, 2019, 3:56:54 PM CDT)

Word Count: 356

2019 APR 01 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- A new study on Oncology - Prostate Cancer is now available. According to news originating from Chicago, Illinois, by NewsRx correspondents, research stated, “Relugolix (TAK-385) is a gonadotropin-releasing hormone (GnRH) antagonist. It is under development and investigation by Myovant Sciences and Takeda for the treatment of endometriosis, uterine fibroids and prostate cancer.”

Our news journalists obtained a quote from the research from the University of Illinois, “Relugolix is a nonpeptide, orally active small-molecule compound that was recently approved in Japan for the treatment of uterine fibroids. Additionally, it is in phase ill trials for endometriosis and prostate cancer. Inhibition of anterior pituitary GnRH receptors results in reduction of the circulating gonadotropins luteinizing hormone and follicle-stimulating hormone, leading to the suppression of estrogen production in women and testosterone production in men.”

According to the news editors, the research concluded: “Considering its oral activity and the cost effectiveness compared to injectable GnRH antagonists, as well as the ability to bypass the initial flare effect of traditional GnRH agonists such as leuprolide acetate, relugolix has been actively explored in several ongoing clinical trials as a promising therapeutic opportunity against hormone-dependent diseases.”

For more information on this research see: Relugolix Gnrh (Lhrh) Receptor Antagonist Treatment of Uterine Fibroids Treatment of Endometriosis-related Pain Treatment of Prostate Cancer. Drugs of the Future, 2019;44(2):131-143. Drugs of the Future can be contacted at: Prous Science, Sau-Thomson Reuters, 398 Provenca, 08025 Barcelona, Spain.

The news correspondents report that additional information may be obtained from A. Al-Hendy, University of Illinois, Dept. of Obstet & Gynecol, 909 S Wolcott Ave, Chicago, IL 60612, United States. Additional authors for this research include A. Elsharoud and M. Ali.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1358/dof.2019.44.2.2927590. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Myovant Sciences Ltd
Takeda GmBH
Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
University of Illinois
Takeda Pharmaceutical Co Ltd

Places

Eastern Asia
North America
Southern Europe
Spain
Japan
United States
Americas
Asia
Europe
Province of Barcelona
Illinois
Barcelona
Chicago

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
            Pharmaceutical Development
      Treatments and Therapies
            Pain Management